

Criteria-Based Consultation Prescribing Program

Kaiser Permanente Northwest Region Criteria for Drug Coverage

semaglutide (Wegovy)

Notes:

- Wegovy is covered under the prescription drug benefit for weight loss **ONLY for Kaiser Northwest members with coverage for medications used to treat weight loss**. Others pay member cash price.
- Contact Pharmacy Services in your home region to confirm your benefits for weight loss medications.
- Quantity Limits: Yes
- ^ Adequate trial is defined as a 3-month treatment duration
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria in adult patients for chronic weight management: Non-formulary **semaglutide (Wegovy)** will be covered on the prescription drug benefit for 4 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; **AND**
 - Diagnosis for chronic weight management; **AND**
 - Patient is 18 years of age or older; **AND**
 - Patient's current weight and BMI are documented in the encounter in which semaglutide (Wegovy) is ordered; **AND**
 - Patient is currently following a diet and exercise program; **AND**
 - BMI greater than or equal to 30 kg/m² or BMI greater than or equal to 27 kg/m² AND has at least one of the following comorbid conditions documented:
 - Hypertension
 - Diabetes
 - Hyperlipidemia
- AND-**
- Patient has failed an adequate trial[^] to at least two of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
 - phentermine
 - diethylpropion
 - phentermine + topiramate or phentermine/topiramate (Qsymia)
 - naltrexone + bupropion or naltrexone/bupropion (Contrave)
- AND-**
- Patient has then failed an adequate trial of semaglutide (Ozempic)

kp.org

Revised: 4/11/24
Effective: 6/6/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

Kaiser Permanente Northwest Region Criteria for Drug Coverage

semaglutide (Wegovy)

Initiation (new start) criteria in pediatric patients for obesity: Non-formulary **semaglutide (Wegovy)** will be covered on the prescription drug benefit for 4 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; **AND**
- Diagnosis of class 2 or class 3 obesity; **AND**
- Patient is 12 to 17 years of age and is at least Tanner 2; **AND**
- Patient's current weight and BMI are documented within the last month from the date in which semaglutide (Wegovy) is ordered; **AND**
- Patient is currently following a diet and exercise program **AND**
- BMI greater than or equal to 35 kg/m² or at least 120% of 95th percentile

-AND-

- Patient has failed an adequate trial[^] to at least two of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
 - phentermine
 - topiramate
 - phentermine + topiramate or phentermine/topiramate (Qsymia)

AND

Patient has then failed an adequate trial or has an allergy, intolerance, or contraindication to semaglutide (Ozempic)

Initiation (new start) criteria for cardiovascular risk reduction: Non-formulary **semaglutide (Wegovy)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient does not have diabetes; **AND**
- BMI 27 or greater; **AND**
- Patient is currently following a diet and exercise program; **AND**
- Patient is 55 to 74 years of age; **AND**
- Patient has a history of STEMI or Type 1 NSTEMI; **AND**
- Occurrence of a STEMI or Type 1 NSTEMI while on semaglutide (Ozempic) 2 mg

Criteria-Based Consultation Prescribing Program

Kaiser Permanente Northwest Region Criteria for Drug Coverage

semaglutide (Wegovy)

Continued use criteria (4 months after initiation and then every 12 months): Non-formulary **semaglutide (Wegovy)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient's updated weight and BMI are recently documented; **AND**
- Patient has achieved greater than 5% weight loss with the past 16 weeks from initiation (reviewed once); **OR**
- Maintains greater than 5% weight loss thereafter (reviewed every 12 months)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **semaglutide (Wegovy)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; **AND**
- Patient is using for chronic weight management/obesity